Department of Mechanical and Aerospace Engineering

Case-Coulter Translational Research Partnership Award


Half to 80 percent of babies born with SCD in countries with limited resources die before age 5, due to lack of diagnosis. The World Health Organization estimates at least 70 percent of those deaths could be preventable with simple, cost-efficient approaches, such as newborn screening, followed by standard treatment and care. HemeChip technology promises to break the diagnostic barrier by providing an affordable, easy-to-use, point-of-care method for newborn screening of SCD and other hemoglobin disorders.

In this project, Dr. Gurkan is working with Jane Little, associate professor of hematology and oncology in the Adult Sickle Cell Disease Program at University Hospitals, and Connie Piccone, assistant professor of pediatric hematology and oncology and clinical director of the Pediatric Sickle Cell Anemia Center at University Hospitals Rainbow Babies and Children’s Hospital.

The 9-year-old Case-Coulter Translational Research Partnership program, a partnership between Case Western Reserve University and the Wallace H. Coulter Foundation, invests in direct funding and support services to help research teams from Case Western Reserve advance products from the laboratory to the marketplace, where they can be available to improve patient care. The funding goes toward preparing projects for commercialization, such as demonstrating technical feasibility, and gauging their market feasibility and industry interest.

More information

Posted on September 24/2015